Patients with type 2 diabetes who received intravitreal anti-vascular endothelial growth factor (VEGF) injections for diabetic retinopathy were more likely to develop systemic adverse events (AEs) ...

STOCKHOLM — A real-world analysis of retrospective data showed that administering more anti-VEGF injections over a 5-year time span to treat macular edema secondary to retinal vein occlusion (RVO) was ...

Use of anti-VEGF therapies varies by both U.S. Census region and patient population, according to research presented at the ...

Sticking to the treatment schedule can be especially difficult. After you’re diagnosed, you usually need to have anti-VEGF injections about once a month, says Purnima Patel, MD, a clinical ...

Please provide your email address to receive an email when new articles are posted on . Mynampati and colleagues measured VEGF levels in 59 eyes of patients with diabetic retinopathy (DR) who had ...

STOCKHOLM — Trial results are demonstrating positive findings for a single intravitreal injection gene therapy for patients with neovascular age-related macular degeneration (nAMD) who previously ...

Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be associated ...

A low risk of adverse safety outcomes was observed in anti–vascular endothelial growth factor (VEGF) intravitreal injections performed in office-based and operating room settings, with a higher rate ...

Treatment strategies for diabetic macular oedema (DME) have evolved over the past decade, with focal laser therapy being largely replaced by intravitreal injections, an observational case series of ...

Adverum Biotechnologies Inc (NASDAQ:ADVM) released data from its ongoing LUNA Phase 2 trial for Ixo-vec in patients with wet age-related macular degeneration (AMD). The 26-week interim analysis was ...